|
[1]
|
Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access
Journal of Medical Economics,
2026
DOI:10.1080/13696998.2026.2623775
|
|
|
|
|
[2]
|
Assessing the health outcomes, productivity gains, and budget impact of anti-PD-(L)1’s in the early stages of cancer treatment in Greece
Frontiers in Oncology,
2026
DOI:10.3389/fonc.2026.1814460
|
|
|
|
|
[3]
|
Preferences of Dermato-oncologists for Adjuvant Therapy in Stage II Melanoma: A Nationwide Discrete Choice Experiment
Acta Dermato-Venereologica,
2025
DOI:10.2340/actadv.v105.44135
|
|
|
|
|
[4]
|
Patient preferences for stages II–IV melanoma treatments in the UK: results from a cross-sectional study
Melanoma Management,
2025
DOI:10.1080/20450885.2025.2570112
|
|
|
|
|
[5]
|
Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
Journal of Cancer Research and Clinical Oncology,
2024
DOI:10.1007/s00432-024-06014-8
|
|
|
|
|
[6]
|
Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment
The Patient - Patient-Centered Outcomes Research,
2023
DOI:10.1007/s40271-023-00635-w
|
|
|
|
|
[7]
|
Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments
PharmacoEconomics,
2022
DOI:10.1007/s40273-022-01198-8
|
|
|
|
|
[8]
|
Preferences for Immunotherapy in Melanoma: A Systematic Review
Annals of Surgical Oncology,
2020
DOI:10.1245/s10434-019-07963-y
|
|
|
|
|
[9]
|
A Guide to Measuring and Interpreting Attribute Importance
The Patient - Patient-Centered Outcomes Research,
2019
DOI:10.1007/s40271-019-00360-3
|
|
|
|
|
[10]
|
Approaches to decision-making among late-stage melanoma patients: a multifactorial investigation
Supportive Care in Cancer,
2018
DOI:10.1007/s00520-018-4395-7
|
|
|
|